96. Crohn disease
2,209 clinical trials,   1,276 drugs   (DrugBank: 240 drugs),   166 drug target genes,   210 drug target pathways

Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00269841
(ClinicalTrials.gov)
May 199622/12/2005An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Fistulizing Crohn's DiseaseA Placebo-Controlled, Repeated-Dose Study of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients With Enterocutaneous Fistulae as a Complication of Crohn's DiseaseCrohn DiseaseDrug: Infliximab 10 mg/kg;Drug: Infliximab 5 mg/kg;Drug: PlaceboCentocor, Inc.NULLCompleted18 Years65 YearsBoth94Phase 3NULL
2NCT00269854
(ClinicalTrials.gov)
June 199522/12/2005An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Crohn's DiseaseA Placebo-Controlled, Dose-Ranging Study Followed by a Placebo-Controlled, Repeated-Dose Extension of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients With Active Crohn's DiseaseCrohn DiseaseDrug: Infliximab 5 mg/kg;Drug: Infliximab 10 mg/kg;Drug: Infliximab 20 mg/kg;Drug: PlaceboCentocor, Inc.NULLCompleted18 Years65 YearsBoth108Phase 2;Phase 3NULL